Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus CORDRAN SP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus CORDRAN SP.
ALA-SCALP vs CORDRAN SP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a 5% solution to the scalp twice daily.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid